Teleflex Incorporated

NYSE:TFX

Medical - Instruments & Supplies

Healthcare
$165.85 +0.83%

+$1.04 today

Market cap
$6.58B
Beta
0.82
P/E (TTM)
-5.5
EPS (TTM)
-$22.79
Dividend yield
1.08%
52W Low $100.18High $139.67

Volume 1.16M

Average 0.80M

TFX Financing Cash Flow

Net cash exchanged with lenders and shareholders through borrowing, repayments, buybacks, and dividends.

Teleflex IncorporatedNYSE: TFX

Financing Cash Flow · Q2 FY2026 · quarter ended Jun 2026

Financing cash flow growth accelerates

Q2 FY2026 financing cash flow of $200.39M (cash outflow) rose 746.7% year over year, ahead of the +219.2% change in trailing-twelve-month financing cash flow. Sequentially, it rose 345.5% from the prior quarter.

Context

  • Financing cash flow amounted to 30.7% of revenue in FY2025, up 16.8 pp from a year earlier.
  • Financing cash flow increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +746.7% holds above the trailing-twelve-month pace of +219.2%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterJun 2026
-$200.39M+345.5% QoQ
Last fiscal yearDec 2025
$611.54M+244.9% YoY
LTMJun 2026
$449.36M+219.2% YoY
Financing Cash Flow past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+746.7%——
1 year+244.9%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Financing Cash Flow history

USD · from the cash flow

Latest · FY2025
611.54M USD
Year-over-year change
+244.9%

Financing Cash Flow vs competitors

How TFX compares with its peers on the latest reported figures

  • Peers report in different currencies, so financing cash flow is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +219.2% is the 6th highest of 11, against a peer median of +261.1%.
  • Financing cash flow amounts to 17.3% of revenue for TFX, versus a peer median of 32.6%.
TFX Competitors
Financing Cash Flow for TFX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ALKSAlkermes plcLTM Sep 2026$1.51B USD+638.5%—86.0%
PCVXVaxcyte, Inc.LTM Jun 2026$1.21B USD-20.7%-86.7%—
ARWRArrowhead Pharmaceuticals, Inc.LTM Sep 2026$776.82M USD+949.7%+45.3%172.3%
CRSPCRISPR Therapeutics AGLTM Sep 2026$719.96M USD+120.5%+122.7%2860.1%
PTCTPTC Therapeutics, Inc.LTM Jun 2026$536M USD+2312.8%+25.4%53.1%
TFXTeleflex IncorporatedLTM Jun 2026$449.36M USD+219.2%—17.3%
TGTXTG Therapeutics, Inc.LTM Sep 2026$292.23M USD+401.7%+512.2%32.6%
BLCOBausch + Lomb CorporationLTM Jun 2026$116.25M USD-52.9%+40.6%2.2%
KRYSKrystal Biotech, Inc.LTM Jun 2026$23.97M USD+591.5%-37.3%5.4%
STVNStevanato Group S.p.A.LTM Jun 2026€9.63M EUR-88.1%—0.8%
MMSIMerit Medical Systems, Inc.LTM Sep 2026$5.06M USD-62.1%—0.3%
Peer median (excluding TFX) —+261.1%+40.6%32.6%

Competitors are the stored peer set for TFX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income485.37M363.14M356.33M69.68M58.53M
Depreciation & Amortization237.36M230.59M242.12M274.6M177.74M
Deferred Income Tax(110.24M)(13.01M)(13.05M)0(100.97M)
Stock-Based Compensation22.94M27.22M31.47M31.35M0
Change in Working Capital127.35M(239.96M)(111.77M)(1.82M)(81.09M)
Accounts Receivables(600K)(38.46M)(15.76M)(27.95M)(85.53M)
Inventory(11.14M)(110.69M)(41.07M)1.72M84.04M
Accounts Payables94.02M(24.79M)(31.26M)9.67M(8.28M)
Other Working Capital45.06M(66.03M)(23.68M)14.74M(71.31M)
Other Non-Cash Items(111.36M)(25.84M)5.55M261.94M286.46M
Operating Cash Flow651.42M342.14M510.64M635.74M340.68M
Capital Expenditures(71.62M)(79.19M)(91.44M)(126.43M)(95.24M)
Acquisitions (Net)220.32M(186M)(588.92M)(120K)(825.15M)
Purchases of Investments(18.42M)(22.3M)(11.3M)(7.3M)(5M)
Sales of Investments7.3M7.3M7.3M7.3M0
Other Investing Activities19.15M22.24M63.13M27.2M76.19M
Investing Cash Flow156.74M(257.94M)(621.23M)(99.36M)(849.19M)
Debt Repayment(634.5M)(145.45M)101.25M(161.5M)982.04M
Common Stock Issued11.1M4.31M000
Common Stock Repurchased0(4.31M)0(200M)(300M)
Dividends Paid(63.65M)(63.79M)(63.9M)(63.54M)(60.27M)
Other Financing Activities(28.77M)(8.27M)1.19M3.12M(10.23M)
Financing Cash Flow(715.82M)(217.51M)38.54M(421.93M)611.54M
Effect of Forex Changes(23.13M)(19.74M)2.86M(9.65M)(29.35M)
Net Change in Cash69.2M(153.05M)(69.19M)104.8M73.68M
Free Cash Flow579.8M262.95M419.2M509.31M245.44M

Teleflex Incorporated

NYSE:TFX

Intrinsic Alpha fair value

Locked

Current Price

$165.85

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.